Saturation Profiling of Drug-resistant Genetic Variants Using Prime Editing

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2024 Nov 12

PMID 39533107

Authors

Younggwang Kim

Hyeong-Cheol Oh

Seungho Lee

Hyongbum Henry Kim

Affiliations

Soon will be listed here.

Abstract

Methods to characterize the functional effects of genetic variants of uncertain significance (VUSs) have been limited by incomplete coverage of the mutational space. In clinical oncology, drug resistance arising from VUSs can prevent optimal treatment. Here we introduce PEER-seq, a high-throughput method based on prime editing that can evaluate the functional effects of single-nucleotide variants (SNVs). PEER-seq introduces both intended SNVs and synonymous marker mutations using prime editing and deep sequences the endogenous target regions to identify the introduced SNVs. We generate and functionally evaluate 2,476 SNVs in the epidermal growth factor receptor gene (EGFR), including 99% of all possible variants in the canonical tyrosine kinase domain. We determined resistance profiles of 95% of all possible EGFR protein variants encoded in the whole tyrosine kinase domain against the common tyrosine kinase inhibitors afatinib, osimertinib and osimertinib in the presence of the co-occurring substitution T790M, in PC-9 cells. Our study has the potential to substantially improve the precision of therapeutic choices in clinical settings.

References

Yang J, Shih J, Su W, Hsia T, Tsai C, Ou S . Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13(5):539-48. DOI: 10.1016/S1470-2045(12)70086-4. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Yun C, Boggon T, Li Y, Woo M, Greulich H, Meyerson M . Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007; 11(3):217-27. PMC: 1939942. DOI: 10.1016/j.ccr.2006.12.017. View

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

Robichaux J, Le X, Vijayan R, Hicks J, Heeke S, Elamin Y . Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021; 597(7878):732-737. PMC: 8481125. DOI: 10.1038/s41586-021-03898-1. View

Campo M, Gerber D, Gainor J, Heist R, Temel J, Shaw A . Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016; 11(11):2022-2026. DOI: 10.1016/j.jtho.2016.06.032. View

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View

10.

Passaro A, Janne P, Mok T, Peters S . Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2022; 2(4):377-391. DOI: 10.1038/s43018-021-00195-8. View

11.

Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V . Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci. 2019; 20(6). PMC: 6470640. DOI: 10.3390/ijms20061431. View

12.

Passaro A, Mok T, Peters S, Popat S, Ahn M, de Marinis F . Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol. 2020; 16(5):764-773. DOI: 10.1016/j.jtho.2020.12.002. View

13.

Yang J, Schuler M, Popat S, Miura S, Heeke S, Park K . Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020; 15(5):803-815. DOI: 10.1016/j.jtho.2019.12.126. View

14.

Janning M, Suptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik J . Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. 2022; 33(6):602-615. DOI: 10.1016/j.annonc.2022.02.225. View

15.

Pretelli G, Claudia Spagnolo C, Ciappina G, Santarpia M, Pasello G . Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need. Int J Mol Sci. 2023; 24(10). PMC: 10218597. DOI: 10.3390/ijms24108878. View

16.

Chakroborty D, Kurppa K, Paatero I, Ojala V, Koivu M, Tamirat M . An unbiased screen for activating epidermal growth factor receptor mutations. J Biol Chem. 2019; 294(24):9377-9389. PMC: 6579474. DOI: 10.1074/jbc.RA118.006336. View

17.

An L, Wang Y, Wu G, Wang Z, Shi Z, Liu C . Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors. Transl Res. 2022; 255:14-25. DOI: 10.1016/j.trsl.2022.11.002. View

18.

Gaudelli N, Komor A, Rees H, Packer M, Badran A, Bryson D . Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017; 551(7681):464-471. PMC: 5726555. DOI: 10.1038/nature24644. View

19.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View

20.

Nishida K, Arazoe T, Yachie N, Banno S, Kakimoto M, Tabata M . Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. 2016; 353(6305). DOI: 10.1126/science.aaf8729. View